Article on Bloomberg re antibiotics: new bill in congress which would make Brilacidin VERY attractive to a big pharma --get this:

Quote:

---

A bipartisan bill introduced in late June in the House of Representatives — known as the Re-Valuing Anti-Microbial Products Act of 2018, or REVAMP — would let a drugmaker that develops an antibiotic meeting certain criteria extend exclusivity on any medicine they want, including a best-seller.

While employing incentives to nudge drugmakers in a specific direction isn’t new (think tropical ailments and rare diseases), the carrot involved here would be unprecedented, potentially worth billions of dollars.

---

https://www.bloomberg.com/view/articles/2018-...rma-payoff